Clinical and immunological predictors of post-rituximab paradoxical pemphigus flare: A prospective cohort study
Indian Journal of Dermatology, Venereology and Leprology · 2024
DOI: 10.25259/ijdvl_894_2023 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, 2024. Verfasst von Vishal Gupta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Pemphigus, Rituximab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Paradoxical flare of pemphigus following rituximab infusion has been reported previously, however, its incidence or risk factors have not been studied in detail.
Objectives
To evaluate the clinical and immunological predictors associated with post-rituximab paradoxical pemphigus flare. Materials and Methods This was a prospective cohort study including adult patients with pemphigus vulgaris or foliaceus who were treated with rituximab. Patients were administered 1000 mg of intravenous rituximab on days 0 and 14 (Rheumatoid arthritis (RA) protocol), with or without oral prednisolone and/or conventional immunosuppressive agents. Baseline clinical and immunological predictors of post-rituximab pemphigus flares were assessed.
Results
Fifty patients (mean age 40.44 ± 12.36 years) with a mean pemphigus disease area index (PDAI) score of 27.8 ± 15.48 were administered rituximab. Post-rituximab flare occurred in 10 (20%) patients after a mean of 14.1 ± 4.33 days after the first rituximab infusion. The mean baseline PDAI score (36.4 ± 11.7 vs. 25.6 ± 15.7, P = 0.02) and serum anti-Dsg1 levels (1216.8 ± 850.1 vs. 592 ± 562.12 RU/mL, P = 0.03) were statistically significantly higher in patients experiencing a flare. Using ROC-curve analysis, a PDAI score of ≥28 (OR 8.3, 95% CI 1.5–44.7) was 80% sensitive and 67.5% specific in predicting post-rituximab flare, while serum anti-Dsg1 level of ≥1137.78 RU/ml had a sensitivity of 60% and specificity of 85%. There was no significant difference in terms of affected body surface area, type of pemphigus, starting prednisolone dose, oral immunosuppressive adjuvant, serum anti-Dsg3, serum anti-AchRM3, and peripheral CD19+ B cell population.
Limitations
Our study is limited by a relatively small sample size. Immunological factors were not evaluated at the time of pemphigus flare. Though these unexpected pemphigus flares are likely to be associated with rituximab infusion, the possibility of spontaneous disease exacerbation cannot be entirely excluded.
Conclusions
Patients with more severe pemphigus or high serum anti-Dsg1 are at risk of post-rituximab paradoxical flare, and may benefit from rituximab administration under close monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Cardiac Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
- Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Zitieren
APA
Gupta, V., Ahuja, R., Sindhuja, T., Imran, S., Kumar Viswanathan, G., Kumar Tembhre, M., Pandey, S., & Khandpur, S. (2024). Clinical and immunological predictors of post-rituximab paradoxical pemphigus flare: A prospective cohort study. Indian Journal of Dermatology, Venereology and Leprology. https://doi.org/10.25259/ijdvl_894_2023
Vancouver
Gupta V, Ahuja R, Sindhuja T, Imran S, Kumar Viswanathan G, Kumar Tembhre M, et al. Clinical and immunological predictors of post-rituximab paradoxical pemphigus flare: A prospective cohort study. Indian Journal of Dermatology, Venereology and Leprology. 2024. doi:10.25259/ijdvl_894_2023
BibTeX
@article{Gupta2024,
author = {Gupta, Vishal and Ahuja, Rhea and Sindhuja, Tekumalla and Imran, Shafaque and Kumar Viswanathan, Ganesh and Kumar Tembhre, Manoj and Pandey, Shivam and Khandpur, Sujay},
title = {Clinical and immunological predictors of post-rituximab paradoxical pemphigus flare: A prospective cohort study},
journal = {Indian Journal of Dermatology, Venereology and Leprology},
year = {2024},
doi = {10.25259/ijdvl_894_2023}
}
EUVIMED